The face of the patent is not the Whole Story: determining effective life of a pharmaceutical patent in the United States ?
This article provides an overview of the factors that may contribute to the effective term of protection for a pharmaceutical product in the USAby patent and by FDA market exclusivities, identifies public and commercial sources for collecting relevant patent term and exclusivity data, and provides a strategy for ensuring that the effective term of protection has been calculated accurately.
pharmaceutical patents fda market exclusivity patent term patent expiry interference infringement terminal disclaimers maintenance fees correction certificates hatchwaxman nce exclusivity orphan drug exclusivity pediatric exclusivity otc switches anda exclusivity